Articles Related to Acute myeloid leukemia
Adverse Drug Events and Predictors of One Year Survival among Adult Patients with Acute Myeloid Leukemia in a Kenyan Tertiary Health Facility
Treatment of acute myeloid leukemia is a challenge because of the adverse drug events associated with therapy and the heterogeneous nature of the subtypes. Research on improving overall survival of patients based on different regimens, reduction of adverse dug events, clinical characteristics and the type of acute myeloid leukemia is critical.
A 51 year old female was referred to our dermatology clinic for a rapidly growing lump on head of 6 weeks duration. On examination we observed a 15 cm diameter erythematous crusted tumor on the forehead with significant bilateral cervical lymphadenopathy. An excision biopsy of the tumor revealed a malignant high grade diffuse undifferentiated infiltrating neoplasm involving the skin and subcutaneous tissue.
Prevalence of the different FAB sub type of Acute Myeloid Leukemia related to hematological parameters in Sudanese
Acute myeloid leukemia (AML) is a heterogeneous disease. Therefore, various parameters are needed to classify this disease into subtypes. The commonly used method for diagnosis and classification is based on FAB criteria using morphology and cytochemical stains. For some of the categories, immunopheno typing is necessary. The aim of present study is to determine the frequency of various sub-types in acute myeloid leukemia using FAB criteria in our Sudanese population. This will aid in the correct diagnosis of acute leukemia and hence proper management of the patients.
Down syndrome or constitutional trisomy 21 was linked to leukemia for the first time in a case report published in 1930 since then, down syndrome has been recognized as one of the most important leukemia – predisposing syndromes and patients with down syndrome and leukemia have unique clinical features and significant differences in treatment response toxicity profiles compared to patients without down syndrome.
Responses and Survival under Pegylated Interferon α2a Treatment for Patients with Post-MPN Acute Myeloid Leukemia and Acute Panmyelosis with Myelofibrosis
We report here for the first time the efficacy of pegylated interferon α2a (Peg-Ifn) as a therapy for patients with myelofibrosis and high blast counts. We treated four patients who were in an accelerated phase of myeloproliferative neoplasms or acute panmyelosis with myelofibrosis using only this drug.
Multiple myeloma is a neoplastic disease characterized by neoplastic proliferation of plasma cells and monoclonal protein expression and related tissue damage.In the presence of overt clinical signs, the disease can easily be diagnosed, however in order to diagnose atypical cases, further investigation is needed with high clinical suspicion.
The DNA mismatch repair (MMR) system is necessary for the maintenance of genomic stability. The MMR system promotes genomic fidelity by repairing base-base mismatches, insertion-deletion loops (IDLs) and heterologies generated during DNA replication and recombination.
Case report A 49-year-old previously healthy man was admitted to the ICU after cardiac arrest following a short history with headache, blurred speech and reduced consciousness. After cardiopulmonary resuscitation perfusion rythm was regained, but the patient didn`t regain consciousness.